Recently, SMYD3 was suggested as a potential prognostic biomarker for diagnosis of prostate cancer [23], breast carcinoma (BrCA) [24] and colorectal cancer (CRC) [25]. This evidence concerns the gene SMYD3 and prostate carcinoma.